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Abstract 
 
The mitochondrial ATPase Inhibitory Factor 1 (hereafter referred to as IF1) 
blocks the reversal of the F1Fo-ATPsynthase to prevent detrimental 
consumption of cellular ATP and associated demise. Herein, we infer further 
its molecular physiology by assessing its protective function in neurons during 
conditions of challenged homeostatic respiration. 
By adopting in vitro and in vivo protocols of hypoxia/ischemia and re-
oxygenation, we show that a shift in the IF1:F1Fo-ATPsynthase expression 
ratio occurs in neurons. This increased IF1 level is essential to induce 
accumulation of the PTEN-induced putative kinase (PINK-1) and recruitment 
of the mitophagic ubiquitin ligase PARK-2 to promote autophagic “control” of 
the mitochondrial population. In IF1 overexpressing neurons ATP depletion is 
reduced during hypoxia/ischemia and the mitochondrial membrane potential 
(ΔΨm) resilient to re-oxygenation as well as resistant to electrogenic, Ca2+ 
dependent depolarization. 
These data suggest that in mammalian neurons mitochondria adapt to 
respiratory stress by upregulating IF1, which exerts a protective role by 
coordinating pro-survival cell mitophagy and bioenergetics resilience. 
 
Key words: F1Fo-ATPsynthase, ATPase Inhibitory Factor 1 (IF1), mitophagy, 
hypoxia/ischemia, re-oxygenation, ΔΨm 
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1. Introduction 
In mammalian cells, energy homeostasis is guaranteed by the efficiency of 
the mitochondrial F1Fo-ATPsynthase which produces the bulk of cellular ATP 
(65). This is particularly relevant in glycolysis-incompetent cells, such as 
neurons, which predominantly rely on this pathway to supply energy (10). 
Herrero-Mendez (37) described how aerobic neurons preferentially shunt 
glucose through the Pentose Phosphate Pathway (PPP) rather than using it 
for glycolysis; this appears to be a mechanism by which the maintenance of 
intracellular anti-oxidant defences (i.e. glutathione (GSH)) is prioritised over 
anaerobic ATP generation (4, 37). Genetically altered mice deficient in 
glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the 
PPP, have lower GSH levels and increased sensitivity to oxidative stress (42). 
This biochemical feature opens the search for alternative protective means 
during O2 deprivation given the continuous degradation of the glycolysis-
promoting enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, 
isoform 3 (PFKFB3) by APC/C-CDH1 (55) makes these cells highly 
susceptible to respiratory impairments and hence to ischemic death. We 
therefore postulated that IF1 could be one of these representing a protective 
pathway through which neurons block the F1Fo-ATPase activity and reduce 
ATP hydrolysis thus avoiding biochemical toxicity and promoting cell survival.  
IF1, even though ubiquitously expressed throughout the body (56), is highly 
expressed in neurons (16, 17). Its protective function in these cell types has 
been already proved (28) and the inhibition of the F1Fo-ATPase recently 
proposed as a target for pharmacological exploitation to prevent hypoxia/re-
oxygenation induced cell death in neurons (41).  
When mitochondrial respiration is compromised, and the membrane potential 
(ΔΨm) disrupted, such as during hypoxia/ischemia (40), the thermodynamic 
equilibrium promotes the reversed activity of the F1Fo-ATPsynthase, which 
then behaves as an ATPase, consuming ATP and translocating H+ from the 
mitochondrial matrix into the intermembrane space in an attempt to preserve 
the ΔΨm (17, 27). IF1 counteracts the hydrolysis of ATP by acting as a 
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reversible, non-competitive inhibitor of the F1Fo-ATPase (27). IF1 changes its 
oligomeric state and binds as a dimer to the enzyme when the 
intramitochondrial pH drops (~6.7) (13, 54, 59). Active IF1 interacts with the α-
, β-, and γ- subunits, blocking the counter-clockwise rotation of the γ- subunit 
and inhibiting the hydrolytic activity of the F1 complex (14, 60) with which 
interacts (7). IF1 is therefore protective in the pathophysiology of ischemia 
whereas ATP wastage accounts for a large proportion of the bio-energetic 
damage (16, 58).  
In spite of this, the underlying molecular events by which targeting of the F1Fo-
ATPase could be protective in hypoxia/re-oxygenation insults has not been 
yet properly addressed. Equally unexplored is whether this entails a role for 
the mitophagic mediator PARK2, which is recruited to mitochondria in an IF1 
dependent fashion (46)  and known to play a preconditioning role for 
mitochondria (71). 
The catabolic process of autophagy has been recently found to target 
dysfunctional mitochondria. This quality-preserving mechanism called 
mitochondrial autophagy or mitophagy consists of the selective degradation of 
mitochondria with dissipated mitochondrial membrane potential (ΔΨm) via the 
autophagosomal-lysosomal pathway (44). Mitophagy is thus a “cleaning up” 
response positioned at the heart of mitochondrial network dynamics, as it 
removes organelles that are unable to re-wire with the rest of the reticulum 
(64). The signalling of this pathway depends on the accumulation of the 
PTEN-induced putative kinase protein 1 (PINK1) in depolarised mitochondria, 
which promotes their engulfment and elimination by autophagosomes 
following recruitment of the E3 ubiquitin-protein ligase PARK2 (49). Other 
PARK2-independent mechanisms of mitochondria removal are now proposed 
but this is the best characterized in neuronal cells. In these, the recent finding 
that externalised mitochondrial phospholipid cardiolipin (CL) acts as an 
elimination signal (23) implies the contribution of “facilitators” that act directly 
or indirectly on this process. By regulating the F1Fo-ATPsynthase and hence 
the ΔΨm, IF1 could act as a facilitator playing a bio-energy adaptation role in 
the asymmetry of mitochondria to autophagy.  We know that when ΔΨm is 
compromised (e.g., during O2 deprivation), homeostatic mechanisms cause 
	   5 
the mitochondrial F1Fo-ATPsynthase to begin acting as an F1Fo-ATPase, 
consuming ATP and translocating H+ out of the mitochondrial matrix to 
preserve ΔΨm thus representing a limiting factor for the bio-energetic 
commitment of mitochondria to quality control. IF1 binding to the F1Fo-ATPase 
to inhibit the hydrolysis of ATP accelerates the dissipation of ΔΨm facilitating 
the recruitment of PARK2 for fast elimination of malfunctioning mitochondria 
(17). The capacity of mitochondria to respond and adapt to metabolic stress 
conditions may be critical to avoid HI-mediated demise, during which 
detrimental redox signalling and parallel mitochondrial impairment leads to 
further deterioration of mitochondrial and cellular function in the delayed 
phase of brain injury accompanied by energy failure. 
Here, by combining in vitro and in vivo approaches we demonstrate that the 
regulation of the IF1 expression level is exploited by mammalian neurons to 
prevent hypoxia/re-oxygenation destabilization of mitochondria and cell 
demise: a protective effect which involves the interplay of mitochondrial 
bioenergetics and mitophagy via timely and effective inhibition of the F1Fo-
ATPase.  
 
2. Results 
 
2.1. IF1 prevents ischemic death in neurons and is upregulated during hypoxia 
 
IF1 blocks the reversal of the F1Fo-ATPsynthase when the respiratory complex 
acts as an ATPase, thus consuming ATP to retain the mitochondrial 
membrane potential (ΔΨm) (Fig. 1a) (17).  IF1 is therefore essential to 
preserve mitochondrial homeostasis in aerobic cells such as neurons in which 
it is highly expressed (Fig. 1b) (16). To test IF1 mediated protection of 
neuronal integrity in hypoxia/ischemia-mimicking conditions, we isolated 
mouse primary cortical neurons and transfected with recombinant YFP or IF1-
YFP cDNA (Supplementary Fig. 1a and b). These were exposed to 3h of 
oxygen and glucose deprivation (OGD) followed by 24h of Re-oxygenation 
(RX); cell viability was then assessed via Propidium Iodide (P.I.) staining (Fig. 
1c and d).  
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IF1 overexpressing neurons reported very low staining, which is indicative of 
increased protection from ischemic cell death compared to control conditions. 
In addition, neurons were exposed to a sublethal insult of OGD for 30 min 
followed by 24h RX to mimic preconditioning (IPC/RX), or OGD for 3h 
followed by 24h RX (OGD/RX) to mimic ischemia. Cell lysates were obtained 
and probed for IF1. Notably, IF1 expression was significantly increased in both 
IPC/RX and OGD/RX groups when compared to control (CTL) (Fig. 1e and f). 
 
2.2 IF1 upregulation leads to PINK-1 accumulation, PARK2 recruitment and 
cell mitophagy 
 
The evidence obtained in primary cultured neurons was repeated also in 
neuronal cell line (SH-SY5Y) (68) in which preconditioning protocols 
upregulate IF1 too, and this quite notably was accompanied by an 
overexpression of PARK2 (Fig. 2a-c).  The modulation in IF1 expression was 
confirmed by means of chemical ischemia that highlighted activation of 
autophagy by LC-3 analysis and consequent reduction of mitochondrial 
volume (Fig. 2d-g). Notably, by exposing this neuronal line to starvation 
protocols (67) there was no effect on the mitochondrial volume fraction 
despite IF1 level being upregulated (Fig. 2h-j): implying the autophagy 
mediated degradation of mitochondria to be prerogative of protocol-conditions 
affecting directly the organelle’s respiratory capacity. Nonetheless, the 
upregulation of IF1 appears specific of the re-oxygenating phases 
(Supplementary Fig. 2a-d) suggesting a molecular redesigning prerogative of 
the re-equilibration phase to homeostatic respiration that was confirmed 
further by the functional analysis of mitochondria.  
We dissected further the potential molecular events forming the basis of this 
adaptive mitophagy response and to this extent we obtained mitochondrial 
fractions isolated from cells exposed to IPC/RX:  both wild type SH-SY5Y or 
SH-SY5Y stably downregulated for IF1 (SH-IF1kd) (Fig.3 a and b). 
This implied that PARK2 recruitment is depending on IF1   expression level 
(Fig. 3c) and thus preceded by the accumulation of PINK-1, accompanied by 
LC3 activation (LC3-II) (Fig. 3 d-g) leading to subtle mitophagy which was 
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assessed by monitoring downregulation of the mtDNA, encoded cytochrome c 
oxidase I (MTCO-1) of the complex IV, which is adopted as control of active 
mitophagy (29, 26) (Fig. 3h). The ablation of MT-CO1, besides accounting for 
a modulation in the mitochondrial mass, also implied a protective targeted 
effect on the elements of the Electron Respiratory Chain (ERC) potentially 
toxic during re-oxygenation (66) sparing the F1Fo-ATPsynthase. Finally, the 
protective role by IF1 in IPC/RX conditions was tested by assessing the 
NAD(P)H-dependent cellular oxidoreductase enzymes which reflect the 
number of viable cells present. It is evident the alternative outcome on cell 
viability in neurons which express IF1 from those who do not (Fig. 3 i). 
 
2.3. IF1 counteracts mitochondrial driven ATP depletion and permeabilization 
 
During hypoxia-ischemic insults the mitochondrial membrane potential (ΔΨm) 
is compromised and the F1Fo-ATPsynthase runs in reverse, consuming ATP 
to preserve ΔΨm (36,57). In order to assess the role of IF1 in this event, in 
control and IF1 overexpressing SH-SY5Y cells we monitored ΔΨm and the 
cellular ATP level, using TMRM (25nM) and MgGreen (5µM) respectively (12, 
47), in conditions of de-oxygenation (hypoxia, mediated by substitution of O2 
with nitrogen) followed by re-oxygenation (2) (Fig. 4a-d). In IF1 overexpressing 
SH-SY5Y, ΔΨm was reduced at a faster rate than control, but in both 
conditions it was restored to initial levels when cells were re-oxygenated. In 
SH-IF1kd (-IF1) cells, the withdrawal of O2 did not alter ΔΨm; instead, this was 
dissipated after re-addition of O2 (Fig. 4 a and b). In the same cohort, a faster 
and greater increase in MgGreen fluorescence was observed, indicating a 
higher rate of ATP consumption by the concomitant, uncontrolled reversal of 
the F1Fo-ATPsynthase (Fig. 4 c and d).  
This prompted us to monitor ΔΨm dissipation in control and IF1 
overexpressing neurons challenged with the electrogenic Ca2+ ionophore 
Ferutinin (70), which stimulates change in mitochondrial permeability by 
overloading mitochondria with Ca2+ (1). In control cells, Ferutinin elicits 
dissipation of ΔΨm (Supplementary Fig. 2e and f) which is prevented by the 
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overexpression of IF1 similarly to the co-administration of Cyclosporin A (11) 
(Supplementary Fig. 2g).  
Following the functional analysis, the outcome on IF1 expression level by 
consecutive conditions of de-oxygenation and re-oxygenation was assessed 
in ex-vivo material isolated from rats undergoing protocols of preconditioning. 
 
2.4. Preconditioned cortex neurons increase IF1  
 
The pattern of IF1 expression was monitored in cerebral samples of wild-type 
rats exposed to: (i) Preconditioning, 30 min of middle cerebral artery occlusion 
(MCAO), followed by 72 hours of Re-Oxygenation (30’ MCAO + 72h REP) 
and (ii) Preconditioning+Ischemia 30 minutes of MCAO, followed by 72h of 
Re-oxygenation and 100 minutes of MCAO (30’ MCAO + 72h REP + 100’ 
MCAO) (Fig. 5a). Protein lysates were probed for IF1 (using ACTIN as control) 
and the immunoblot analysis showed a significant increase of IF1 expression 
in the ischemic model, which was greater when preceded by preconditioning 
(Fig. 5b and c). From the same animals, sections of the ipsilateral 
temporoparietal cortex were obtained and double stained for the neuronal 
marker Neuronal Nuclear Antigen (NeuN) (32) and IF1. In these samples, it 
was evident that the total neuronal population (cells positive to NeuN) 
expressed IF1 and the co-localisation between the two proteins was 
significantly greater in both conditions compared to control (Fig. 5d and e).  
This further ex-vivo data suggests that neurons, during conditions challenging 
their mitochondrial and cellular respiratory homeostasis, adapt by modulating 
the level of IF1, expression. 
 
3. Discussion 
 
Ischemic cerebrovascular diseases are among the prominent cause of 
morbidity in western countries, and the third most common cause of death in 
elderly patients (39). Ischemic damage of nerve cells leads to the activation of 
complex signalling pathways and transduction mechanisms that still remain 
partially defined. Early phenotypic, ischemic-dependent observations are of a 
biochemical nature; the most prominent of these is loss of ATP (63), as within 
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minutes after inhibiting oxygen supply its levels are greatly diminished (62). 
Mitochondrial consumption of ATP, due to the reversal of the F1Fo-
ATPsynthase, plays a prominent role in this, leading to (i) disruption of the 
Na+/K+ gradient (20, 43, 45, 50), (ii) profound electrolyte imbalance (6, 18) 
and (iii) alteration of Ca2+ homeostasis preservation (53). The accumulation of 
intracellular Ca2+ leads to a pathological mitochondrial overloading, which 
further deregulates their function and structure with concomitant free-radical 
generation (5). Targeting ATP dissipation is therefore a logical point of 
intervention in the attempt to treat ischemic conditions, particularly in neurons 
where glycolysis is reported to be inefficient (4, 37). Secondary energy failure 
(33) accompanies brain injuries and is likely contributed to by reversal of the 
F1Fo-ATPsynthase. IF1, which blocks the reversal of the F1Fo-ATPsynthase 
and the consequent mitochondrial-driven hydrolysis of ATP (Fig. 1a) (17), can 
impinge upon this process and represents the major player in this 
endogenous protective pathway (21). IF1 may therefore mitigate the adverse 
effects in neurons acting at multiple levels and preserving cell vitality during 
and after situations of energy crisis. By mediating both short-term and long-
term neuroprotective effects it could improve long-term neurologic recovery 
via repair and continued survival function of neuronal cells. 
In this original manuscript we have indeed shown that in neurons subjected to 
ischemic/hypoxia and re-oxygenation IF1 is upregulated. This shift in ratio 
occurs in primary cultured neurons as well as in cell lines resembling the 
neuronal phenotype (SH-SY5Y) (Fig. 1 and 2). In addition, ex-vivo analysis of 
lysates and tissue sections of rat cortexes, subjected to middle cerebral artery 
occlusion (MCAO) with re-oxygenation (51, 52) demonstrate that the 
overexpression of IF1 occurs in preconditioning-like treatments (Fig. 5). 
Preconditioning is a well-characterized method for promoting tissue resistance 
to the acute loss of oxygenation (Grover et al., 2004), and the increased 
IF1:F1Fo-ATPsynthase expression ratio is indicative of a molecular adaptation 
for self-protection. 
The response to abrupt imbalance in cellular bio-energetics does seem to 
lead, therefore, to the stabilization of an energy preserving gene such as IF1 
which is indeed already abundantly expressed in neurons (16). 
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The in vitro assays proved the beneficial effects of IF1 on the cellular survival 
rate in line with recent reports (28) but with novel insights into mitochondrial 
metabolism, which argues for the fine-tuned inhibition of the F1Fo-ATPase 
(16) as an indispensable protective mechanism to preserve ATP and regain 
physiological ΔΨm  during re-booting of cell respiration (Fig. 4). This is in line 
with preceding work in which we showed that the pharmacological, selective 
inhibition of the F1Fo-ATPase is protective if targeted against the reverse 
mode of the enzyme (41). Interestingly, IF1 overexpressing mitochondria do 
retain ΔΨm also during exposition to the electrogenic agent Ferrutinin (70, 1) 
mimicking, quite surprisingly, the Cyclosporine A (CsA) (Supplementary Fig. 
2). This is an interesting observation in light of the most recent literature which 
associates the events of mitochondrial permeability, linked to the CsA 
sensitive pore, with the F1Fo-ATPsynthase and its molecular re-assembly (30, 
25) in which a contribution by IF1 has not been, hitherto, speculated. 
The IF1 mediated neuroprotection does associate, anyway, with the 
accumulation of PINK-1 and recruitment of PARK2 and the execution of cell 
mitophagy (46). IF1 overexpression is thus accompanied by the activation of 
targeted autophagy towards mitochondria whose beneficial nature in 
preconditioning is documented (36). 
Furthermore, in subsequent events of O2 deprivation and re-addition, IF1 thus 
promotes the mitophagic targeting (hence removal) of specific mitochondrial 
components (Figs. 2 and 3): the cytochrome c oxidase I (MT-CO1) of the ERC 
Complex IV, which is proposed to contribute the acute generation of Reactive 
Oxygen Species during the re-oxygenation (3) phases (Fig. 3c). MT-CO1 
instead appears stabilized in SH-IF1KD neurons (Fig. 3c).The evidence that 
the F1Fo-ATPsynthase remains untouched further confirms the selective 
nature of mitophagy within this process. 
In post-mitotic neurons mitophagy, which is yet ill-defined (8, 9, 61, 69), is 
considered to be a late-occurring event following cells challenge by mitophagy 
triggers (it is not fully occurring before 18h after chemical dissipation of ΔΨm 
obtained following CCCP treatment) (15). In line with this, the mitophagy-
associated events of degradation do occur at late time point of re-oxygenation 
(e.g. 24h). Furthermore, mitophagy appears to be a specific response to 
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hypoxia/re-oxygenation scenario and not in starvation-like conditions despite 
the concurrent upregulation of IF1 (Fig. 2). 
The increased IF1:F1Fo-ATPsynthase expression ratio, promoted and 
sustained by metabolic preconditioning, could therefore represent a 
biochemical reformatting in highly oxidative cells, of which neurons are the 
archetype. This mechanism is likely to be aimed at: (i) compensating the 
inability to synthesize ATP via anaerobic glycolysis, (ii) preserving 
mitochondrial and cellular metabolism when respiration is compromised, and 
(iii) removing potentially toxic mitochondrial elements during re-oxygenation. 
We have therefore here provided molecular and physiological evidence that 
IF1 does act in the ischemic/hypoxia and re-oxygenation of neurons 
interplaying clearance of toxic mitochondria with bio-energy fine-tuning, as 
depicted in the working model reported in Fig. 6. This IF1-dependent 
mechanism for neuroprotection, could and should possibly be exploited for the 
treatment of hypoxia/re-oxygenation injuries of the brain. 
 
4. Materials and Methods 
 
Chemicals were purchased from Sigma unless stated otherwise, fluorescent 
dyes from Molecular Probes. Antibodies used were IF1 (MitoSciences), ATPβ 
(Abcam), and β-Actin (Sigma), NeuN (Millipore), GAPDH (Abcam), LC3 
(NovusBio), MTCO-1 (Abcam), PARK2 (Sigma-Aldrich), Beta-III Tubulin 
(Sigma-Aldrich).  Alexa fluor 546 anti-mouse IgG, Alexa-fluor 488 anti-rabbit 
IgG and Alexa-fluor 643 anti-mouse IgG were obtained from Molecular Probes 
(Eugene, OR). Ferrutinin (Enzo-Life Sciences), MgGreen and TMRM (Life-
Techonologes). 
 
4.1. Plasmids and Transfections  
 
The pCMV-SPORT6-IF1 plasmid was used for overexpression of wild type IF1 
in human cell lines. IF1-YFP (pEYFP-N1- IF1) was obtained from Mutagenex 
Inc. (NJ, USA); Downregulation of IF1 in human cell lines was achieved by 
using the pGIPZ shRNA vector V3LHS_409663 (target sequence: 5’-
	   12 
ATGGTTCTGGTTTAACTAATA -3’) purchased from Quiagen. All 
transfections were performed using Lipofectamine 2000 reagent (Invitrogen) 
according to manufacturer’s specifications. 
 
4.2. MTT assay  
 
 Cell viability was measured using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) as described in (34). SH-SY5Y and SH-
SY5Y IF1-/- cells were plated (50,000 cells per condition, in triplicate) in 24 
well plates 3 days prior to treatment. After 30min and 3h OGD (as described 
in the Materials and Methods section), followed by 24h of re-oxygenation, 
MTT assay was performed to determine cell survival. Briefly, after treatments 
cell medium was removed and cells were incubated in 0,5mg/ml MTT solution 
for 1 hour at 37°C and 5% CO2. To stop incubation, MTT solution was 
removed and 1ml dimethyl sulfoxide (DMSO) was added to solubilize the 
formazan product. The absorbance was monitored at 595nm with a Varioscan 
Lux fluorimeter (Thermo Fisher Scientific, US). The data are expressed as the 
percentage of viable cells normalized to non-treated controls. 
 
4.3. Animal models and cortical neurons preparation  
 
All procedures involving animal care or treatments were approved by the 
Italian Ministry of Health (Rome, Italy) and performed in compliance with the 
guidelines of the European Communities Council Directive of 24 November 
1986 (86/609/EEC). All efforts were made to minimize animal suffering and to 
reduce the number of animals used. Neurons were obtained and cultured 
accordingly to published protocols (19).  
 
4.4. Cell Lines 
 
 SH-SY5Y cells were purchased from American Type Culture Collection 
(ATCC, Rockville, MD, USA) and were grown in standard DMEM medium 
supplemented with 10% fetal bovine serum (Life Technologies, 10.082.147), 
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100 U/mL penicillin, and 100 mg/mL streptomycin (Life 
Technologies,15140122) at 37°C and 5% CO2. 
 
4.5. Transient focal ischemia and ischemic preconditioning 
 
 Transient focal ischemia was induced as previously described (48) by suture 
occlusion of the middle cerebral artery (MCA) in male rats anesthetized using 
1.5% sevoflurane, 70% N2O, and 28.5% O2. Achievement of ischemia was 
confirmed by monitoring regional cerebral blood flow through laser Doppler 
(PF5001; Perimed). Animals not showing a cerebral blood flow reduction of at 
least 70% were excluded from the study. Rats were divided into two 
experimental groups: (1) preconditioned and (2) preconditioned ischemic rats 
(subjected to preconditioning plus tMCAO). The sham-operated animals 
underwent the same experimental conditions except that the filament was not 
introduced; in the ischemic group, the MCA was occluded for 100 min; in the 
pre-conditioned ischemic group, rats were subjected to 30 min of tMCAO 72h 
before 100 min of tMCAO. All animals were killed 24h after 100 min of 
tMCAO. The brains were cut into 1mm coronal slices with a vibratome 
(Campden Instrument, 752 M). Sections were incubated in 2% TTC for 20 min 
and in 10% formalin overnight.  
 
4.6. Combined O2 and glucose deprivation 
 
Preconditioning and ischaemic insults were reproduced in vitro by exposing 
cells to 30 min and 3 hours (respectively) of oxygen glucose deprivation 
(OGD) (2). OGD was performed in a medium previously saturated with 95% 
N2 and 5% CO2 for 20 min and containing NaCl 116 mmol/L, KCl 5.4 mmol/L, 
MgSO4 0.8 mmol/L, NaHCO3 26.2 mmol/L, NaH2PO4 1 mmol/L, CaCl2 1.8 
mmol/L, glycine 0.01 mmol/L, and 0.001 w/v phenol red (22). Hypoxic 
conditions were maintained using a hypoxia chamber (temperature 37°C, 
atmosphere 5% CO2 and 95% N2). At the end of the incubation, the cells were 
either immediately lysed for Western Blot analysis or incubated for 24h in 
normoxic conditions using culture medium containing normal levels of O2 in a 
	   14 
CO2 incubator at 37°C (re-oxygenation - Rx) followed by lysis. Whole cell 
lysates were prepared in Radioimmunoprecipitation  (RIPA) buffer and 
mitochondrial fractions in isotonic sucrose buffer containing 250mM sucrose, 
20mM HEPES (7.4), 10mM KCl, 1.5mM MgCL2, 1mM EDTA and 1mM EGTA.  
To induce starvation, cells were kept in serum-free media for 24 hours prior to 
the analysis. For chemical ischemia, the culture medium was replaced by an 
ischemic buffer (115 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 2 mM 
NaH2PO4, 25 mM NaHCO3, pH 7.4) plus 1mM NaCN during 1, 2 and 24 
hours. 
 
4.7. Western blotting 
 
Cortical samples were harvested from brains of rats subjected to (a) 
preconditioning (b) 100 min of tMCAO, and (c) preconditioning plus ischemia. 
Rat brain samples were homogenised in a lysis buffer (50 mmol/L Tris–HCl, 
pH 7.5, 100 mmol/L NaCl, 1% Triton X-100) containing protease and the 
phosphatase inhibitor. After centrifugation at 12,000 g at 4 °C for 5 min, the 
supernatants were collected.  
SH-SY5Y cells and cortical neurons were washed in PBS and collected by 
gentle scraping in ice-cold RIPA buffer to detect proteins. Protein 
concentration was estimated using the Bradford reagent. Following this 50 µg 
of protein was mixed with a Laemmli sample buffer and boiled at 95 °C for 2 
min. The samples were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis and transferred to nitrocellulose membranes. Blots were 
probed with antibodies diluted in 1% bovine serum albumin in tris buffered 
saline (TBS-T) overnight (4 °C). Then, they were detected using horseradish 
peroxidase-conjugated secondary antibody (1:2000; Cell Signaling; 60 min at 
room temperature (RT) in 5% non-fat milk) and an enhanced luminescence kit 
(Amersham Pharmacia Biotech, NJ, USA). 
Cells treated with chemical ischaemia and starvation were collected after 
different time point and conditions by trypsinization and dissolved with lysis 
buffer (50mM Tris, 150mM NaCl, 1% triton, pH 8) on ice for 30 min. The 
supernatant of the lysates was collected after centrifugation at 16,000 g at 
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4°C for 10 min. Sample proteins were quantified using a bicinchoninic acid 
protein assay kit (Thermo Scientific, 23227). Proteins (20 µg) were resolved in 
12% polyacrylamide gel (SDS-PAGE) and transferred to a nitrocellulose 
membrane. The membrane was blocked in 3% non-fat dry milk or 5% of BSA 
(following manufacturer recommendation) in TBST (50 mM Tris, 150 Mm 
NaCl, 0.05% Tween 20 (Sigma Aldrich), pH 7.5) for 1 h then incubated with 
the appropriate diluted primary antibody at 4°C overnight: mouse anti-ATPIF1 
(Abcam, ab110277) 1:1000, mouse anti-ATP5B (Abcam, ab14730) 1:5000, 
rabbit anti-LC3 (Abcam, ab48394) 1:1000, mouse anti-ß Actin (Abcam, 
ab8226) 1: 2000. The membrane was washed in TBST (3 × 15 min at room 
temperature) and then incubated with the corresponding peroxidase-
conjugated secondary antibody for 1h at room temperature. After further 
washing in TBST, the blot was developed using an ECL Plus Western blotting 
detection kit (Amersham, GE Healthcare Life Sciences, RPN2133). 
Immunoreactive bands were analysed by performing densitometry analysis 
with ImageJ software (NIH, Bethesda, MD, USA). 
 
4.8. Tissue and cell immunofluorescence 
 
Rats were anesthetized with chloral hydrate (300 mg/kg, intraperitoneally) and 
perfused transcardially with 4% paraformaldehyde. Brains were post-fixed for 
24 hours, transferred in 30% sucrose /PBS solution at 4◦C until it sank and 
sectioned using a sliding freezing microtome (Leica, Wetzlar, Germany). The 
brains were sectioned coronally at 40 µm, collected in PBS and stored at 4°C 
until usage. After blocking, sections were incubated with primary and 
secondary antisera before being mounted on slides, air-dried and gel 
mounted (Biomeda Corp., Foster City, CA, USA).  
Cortical neurons and cells transiently transfected with IF1 or control plasmids 
were cultured on glass coverslips for 24h, once exposed to combined O2 and 
glucose deprivation or chemical hypoxia were washed twice in cold 0.01 M 
PBS (pH 7.4) and fixed in 4% (w/v) paraformaldehyde for 20 min at RT. 
Following three washes in PBS, cells were blocked with 3% (w/v) bovine 
serum albumin and 0.01% Triton-X (Biorad, Milan, Italy) for 2h at RT. All 
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coverslips were then incubated with a mix of primary antibodies according to 
the experiment and left at 4 °C overnight. Following three washes in PBS, the 
coverslips were incubated in the dark with a mix of the following secondary 
antibodies (dilution 1:200) for 1h at RT. After the final wash, the coverslips 
were mounted with Prolong Gold antifade reagent containing DAPI for nuclei 
visualisation (Invitrogen) and analysed under a confocal laser-scanning 
microscope (Leica SP5). Confocal acquisition settings were identical among 
the different experimental cases. For production of figures, brightness and 
contrast of images were adjusted by applying the same values. Tissue image 
acquisitions were performed on frontal cortex (somatosensory area) after 
inspection of cortical and hippocampal regions to evaluate the presence of 
degenerative areas. Boundaries and subdivisions of cortical and hippocampal 
structures were identified by visual inspection on the base of the DAPI 
histofluorescence or through NeuN staining using a rat brain atlas (Paxinos). 
Image analysis was performed by using Imaris Suite 7.4® (Bitplane A.G., 
Zurich, Switzerland) software (surface and spot modules) or ImageJ 1.4 on six 
different images derived from each experimental group and performed under 
visual control to determine thresholds that subtracts background noise and 
takes into account cellular structures. The evaluation of mitochondrial relative 
fluorescent intensity was carried out as previously described (24). 
 
4.9. Live Imaging Experiments  
 
The Tetramethyl rhodamine methyl ester (TMRM) was used in ‘redistribution 
mode’ to monitor ΔΨm (16). Redistribution of the dye from the mitochondria 
and cytosol was monitored continuously using Inverted Zeiss Axiovert 
microscope with a motorised stage for multi-location work and environmental 
chamber in which O2 was substituted with N2 during hypoxia and re-added 
during re-oxyegnation. Cellular ATP levels were indirectly measured using the 
cell permeant, green fluorescent Mg2+ indicator Magnesiun GreenTM, AM, the 
emission intensity of which increases, without a shift in wavelength, after 
binding to Mg2+. Briefly, cells were loaded with 5µM Magnesiun GreenTM  for 
30 min at 37°C, 5% CO2. After loading, cover glasses were washed three 
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times with recording medium and mounted within an Attofluor® metal cell 
chamber for microscopy (Molecular ProbesTM, Thermo Fisher Scientific, A-
7816). Continuous live imaging was carried out using a Zeiss UV 510 confocal 
laser scanning microscope (inverted configuration on an Axiovert 200 frame) 
equipped with a thermostatted chamber (37°C) and a Fluar 40x/1.30 oil 
immersion objective (72).  
 
4.10. Statistical analysis 
 
This was performed with 2-way ANOVA, followed by Newman–Keuel's test. 
Statistical significance was accepted at the 95% confidence level (*p < 0.05, 
**p< 0.01 and ***p< 0.001). 
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Legends to Figures  
 
Fig. 1: IF1 mechanism of action and its exploitation in primary neurons. 
(a) IF1  mechanism of action (b) IF1 and β-III tubulin staining in cortical 
neurons of mice. (c) Propidium/Iodide (P.I.) staining of cortical neurons mock 
transfected with YFP or IF1-YFP plasmid, exposed to 3 h oxygen and glucose 
deprivation (OGD) followed by 24h re-oxygenation (RX). (d) The bar graph 
reports the P.I. quantification expressed as % of control (mean value±SEM,	  
SH-SY5Y CTL=100±0 SH-SY5Y OGD/RX=221±11 SH-SY5Y +IF1=102±0     
SH-SY5Y +IF1 OGD/RX=162±8 n=3 *p< 0.05, ***p< 0.001). (e) A 
representative Western blot of IF1, F1Fo-ATPsynthase β-subunit and β-actin in 
full cell lysates of cortical neurons control and exposed to IPC/RX and 
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OGD/RX: mature cortical neurons were exposed to 30min (IPC) and 3h 
(OGD) of oxygen and glucose deprivation followed by 24h normoxia (RX) 
prior to cell lysis (f) The bar graph reports the quantification of IF1 expression 
in cortical neurons. Data were normalized on the basis of β-actin levels and 
expressed as IF1/β-actin ratio (mean value±SEM, SH-SY5Y 
CTL=0,464±0,021 SH-SY5Y IPC/RX=0,710±0,030 SH-SY5Y 
OGD/RX=1,234±0,048 n=3  **p< 0.01). 
 
Fig. 2: IF1 upregulation in SH-SY5Y cells leads to mitophagy activation in 
a hypoxia/re-oxygenation specific manner.  
(a) A representative Western blot of IF1, F1Fo-ATPsynthase β-subunit, PARK2 
and GAPDH in full cell lysates of SH-SY5Y cells control and exposed to 
IPC/RX and OGD/RX:  SH-SY5Y were exposed to 30min (IPC) and 3h (OGD) 
of oxygen and glucose deprivation followed by 24h normoxia (RX) prior to cell 
lysis. (b) The bar graph reports the quantification of IF1 expression, 
normalized on the basis of GAPDH levels and expressed as IF1/GAPDH ratio 
(mean value ±SEM, CTL=1,194±0,065 IPC/RX=2,111±0,098 
OGD/RX=2,710±0,105 n=5 **p< 0.01). (c) The bar graph reports the 
quantification of PARK2 expression, normalized on the basis of GAPDH levels 
and expressed as PARK2/GAPDH ratio (mean value ±SEM, 
CTL=0,329±0,013 IPC/RX=1,784±0,072 OGD/RX=2,565±0,081 n=5 **p< 
0.01).  (d) A representative Western blot of IF1, F1Fo-ATPsynthase β-subunit, 
LC3 isoforms I and II and β-actin in full cell lysates of SH-SY5Y cells control 
and incubated for 1h, 2h and 24h in ischaemic buffer with 1mM NaCN. (e) 
The bar graph reports the quantification of IF1 expression, normalized on the 
basis of β-actin levels and expressed as IF1/β-actin ratio (mean value ±SEM, 
CTL=1,508±0,126 ISCH.B.1h=2,095±0,162 ISCH.B.2h =2,728±0,170 
ISCH.B.24h=0,751±0,112  n=3 *p<0.05, ***p<0.001). (f) The bar graph 
reports the quantification of F1Fo-ATPsynthase β-subunit expression, 
normalized on the basis of β-actin levels and expressed as ATPβ/β-actin ratio 
(mean value ±SEM, CTL=0,723±0,035 ISCH.B.1h=0,740±0,070 ISCH.B.2h 
=1,003±0,088 ISCH.B.24h=0,343±0,099  n=3 **p<0.01). (g) The bar graph 
reports the quantification of LC3-isoforms I and II expression, normalized on 
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the basis of β-actin levels and expressed as LC3-II/LC3-I ratio (mean value 
±SEM, CTL=1,167±0,178 ISCH.B.1h=1,527±0,262 ISCH.B.2h =1,533±0,192 
ISCH.B.24h=7,291±1,569  n=3 **p<0.01).  (h) A representative Western blot 
of IF1, F1Fo-ATPsynthase β-subunit, LC3 isoforms I and II and β-actin in full 
cell lysates of SH-SY5Y cells control and starved in serum free medium for 
24h. (i) The bar graph reports the quantification of IF1 expression, normalized 
on the basis of β-actin levels and expressed as IF1/β-actin ratio (mean value 
±SEM, CTL=2,690±0,310 STARV24h=4,304±0,417 n=4 *p<0.05). (j) The bar 
graph reports the quantification of LC3-isoforms I and II expression, 
normalized on the basis of β-actin levels and expressed as LC3-II/LC3-I ratio 
(mean value ±SEM, CTL=1,000±0 STARV24h=1,677±0,034 n=3  **p<0.01). 
 
Fig. 3: Mitochondrial PARK-2 recruitment during de-oxygenation and re-
oxygenation is IF1 dependent. 
(a) SH-SY5Y cells were stably transfected with pGIPZ GFP labeled vector (as 
described in Section 4) and IF1 downregulation (in SH-IF1kd cells) confirmed 
by Western Blot analysis (b) The bar graph reports the quantification of IF1 
expression, normalized on the basis of GAPDH levels and expressed as 
IF1/GAPDH ratio (mean value±SEM, SH-SY5Y =1,032±0,002 SH-IF1kd 
=0,009±0 n=2 ***p<0.001). (c) A representative Western blot of IF1, PARK2, 
PINK-1, MTCO-1, LC3 isoforms I and II and F1Fo-ATPsynthase β-subunit in 
mitochondrial fractions of SH-SY5Y cell lysates. SH-SY5Y and SH-IF1kd cells 
are divided in two groups: control and exposed to 30min (IPC) of oxygen and 
glucose deprivation followed by 24h normoxia (RX) prior to cell lysis and 
mitochondrial fraction isolation. (d) The bar graph reports the quantification of 
IF1 expression, normalized on the basis of IF1Fo-ATPsynthase β-subunit 
levels and expressed as IF1/ATP-β ratio (mean value±SEM, SH-SY5Y 
=0,616±0,001 SH-SY5Y IPC/RX=0,951±0,016 SH-IF1kd=0,142±0,006 SH-
IF1kd IPC/RX=0,099±0,001 n=4 *p<0.05 ***p<0.001). (e) The bar graph 
reports the quantification of PARK2 expression, normalized on the basis of 
F1Fo-ATPsynthase β-subunit levels and expressed as PARK2/ATP-β ratio 
(mean value±SEM, SH-SY5Y=0,620±0,006 SH-SY5Y IPC/RX=1,372±0,003 
SH-IF1kd=1,002±0,006 SH-IF1kd IPC/RX=0,440±0,003 n=4 ***p<0.001).  (f) 
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The bar graph reports the quantification of PINK-1 expression, normalized on 
the basis of F1Fo-ATPsynthase β-subunit levels and expressed as PINK-1/ 
ATP-β ratio (mean value±SEM,	   SH-SY5Y=0,454±0,007 SH-SY5Y 
IPC/RX=0,686±0,007 SH-IF1kd =0,600±0,010 SH-IF1kd IPC/RX=0,392±0,002 
n=4 ***p<0.001).  (g) The bar graph reports the quantification of LC3-isoforms 
I and II expression, normalized on the basis of ATP-β levels and expressed as 
LC3-II/LC3-I ratio (mean value±SEM, SH-SY5Y=0,230±0,009 SH-SY5Y 
IPC/RX=1,351±0,018 SH-IF1kd =0,313±0,003 SH-IF1kd IPC/RX=2,869±0,165 
n=4 ***p<0.001). (h) The bar graph reports the quantification of MTCO-1 
expression, normalized on the basis of ATP-β levels and expressed as 
MTCO-1/ ATP-β ratio (mean value±SEM, SH-SY5Y=0,666±0,012 SH-SY5Y 
IPC/RX=0,616±0,003 SH-IF1kd=0,722±0 SH-IF1kd IPC/RX=1,023±0,029 n=4 
***p<0.001). (i) Cell viability upon IPC/OGD treatment was measured using 
MTT assay and expressed as % of cell survival. The bar graph reports 
quantification of cell survival normalized for the non-treated control values 
(mean value±SEM, SH-SY5Y CTL=1±0,004 SH-SY5Y IPC/RX=0,940±0,142 
SH-SY5Y OGD/RX=0,524±0,019 SH-IF1kd CTL=1±0,004 SH-IF1kd 
IPC/RX=0,606±0,118 SH-IF1kd OGD/RX=0,355±0,130, n=3, *p<0.05, 
**p<0.01).  
 
Fig. 4. IF1 protects neuronal mitochondrial metabolism from oxygen 
deprivation and re-oxygenation  
(a) ΔΨm dynamics in SH-SY5Y cells control, IF1 overexpressing or 
downregulated for IF1 following hypoxia and re-oxygenation.  (b) The bar 
graph represents quantification of average traces displaying TMRM 
fluorescence measured from the mitochondria in response to hypoxia and re-
oxygenation, presented as the ratio between the initial TMRM fluorescence 
and the TMRM fluorescence achieved after treatment. Data are expressed as 
mean value±SEM, Hypoxia control=0,76±0,01 Hypoxia +IF1=0,43±0,02 
Hypoxia –IF1= 0,84±0,01 Re-oxygenation control=0,93±0,01 Re-
oxygenation+IF1=0,91±0,01 Re-oxygenation –IF1=0,14±0,01 n=3  **p< 0.01. 
(c) ATP levels were assessed indirectly using an indicator of free magnesium, 
MgGreen (5  µM). The graph shows representative traces for SH-SY5Y cells 
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control, IF1 overexpressing or downregulated for IF1 following hypoxia. (d) 
The bar graph represents normalized values of MgGreen fluorescence, 
expressed as mean value±SEM, Hypoxia control=1,24±0,02 Hypoxia 
+IF1=1,05±0,09 Hypoxia –IF1= 1,41±0,01 n=3 **p< 0.01.  
 
Fig. 5. IF1 pattern of expression in rat cerebral cortex exposed to 
preconditioning protocols 
(a) Section of brain cortex in sham operated rats and rats exposed to 
preconditioning (30’ MCAO) and preconditioning+ischemia (30'MCAO+72h 
REP+100'MCAO). (b) A representative Western blot of IF1 and β-actin in 
lysates of brain cortex isolated from the four experimental conditions. (c) Bar 
graph reporting the quantification of IF1 expression in portions of brain cortex. 
Data were normalized on the basis of β-actin levels and expressed as 
percentage of controls (mean value±SEM, SHAM=0,469±0,015 
PREC=0,559±0,018 PREC+ISCH=1,205±0,006 n=3 ***p< 0.001. (d) Double 
staining of IF1 and Neu-N in section of brain cortex in the four experimental 
conditions. (e) The bar graph reports the quantification of IF1 fluorescence in 
the ipsilateral temporoparietal cortex portion (mean value±SEM, 
SHAM=100±0 PREC=155,46±14,64 PREC+ISCH=173,53±16,21 n=3 *p< 
0.05, **p< 0.01 ).  
 
Fig. 6. Working model for the neuroprotective role of IF1 
The cartoon depicts physiopathology of neurons exposed to ischemia-
hypoxia/re-oxygenation. Preconditioned neurons upregulate mitochondrial IF1 
to limit the reverse mode of action of the F1Fo-ATPsynthase and 
concomitantly promoting the PARK2 dependent removal of toxic organelles. 
The exploitation of this pathway reduces the susceptibility of neurons to 
ischemic cell death that instead occurs in neurons devoid of IF1. 
 
Legends to Supplementary Figures  
 
Supplementary Fig. 1. Recombinant IF1 upregulation in primary cortical 
neurons 
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(a) IF1 staining in cortical neurons mock transfected with YFP and expressing 
IF1-YFP and (b) The bar graph reports the quantification of IF1 fluorescence 
(mean value±SEM, YFP=100±0 IF1=210,75±11,64 n=3 *p< 0.05,).  . 
 
Supplementary Fig. 2. IF1 profiled expression during re-oxygenation and 
mediated protection to electrogenic depolarization of mitochondria 
(a) A representative Western blot of IF1 and F1Fo-ATPsynthase β-subunit in 
mitochondrial fractions of SH-SY5Y cell lysates. SH-SY5Y are divided in 
following groups: control, exposed to IPC without re-oxygenation (-RX) and 
exposed to IPC followed by 24h of re-oxygenation (+RX). (b) The bar graph 
reports the quantification of IF1 expression, normalized on the basis of F1Fo-
ATPsynthase β-subunit levels and expressed as IF1/ATP-β ratio (mean 
value±SEM, +Rx CTL=0,616±0,001 +Rx IPC=0,950±0,016 -Rx 
CTL=0,800±0,034 -Rx IPC=0,735±0,042 n=2 ***p<0.001). (c) A 
representative Western blot of IF1 and GAPDH in full cell lysates of SH-SY5Y 
cells. SH-SY5Y are divided in following groups: control, exposed to IPC 
without re-oxygenation (-RX) and exposed to IPC followed by 24h of re-
oxygenation (+RX). (d) The bar graph reports the quantification of IF1 
expression, normalized on the basis of GAPDH levels and expressed as 
IF1/GAPDH ratio (mean value±SEM, +Rx CTL=1,194±0,065 +Rx 
IPC=2,111±0,098 -Rx CTL=0,754±0,009 -Rx IPC=0,937±0,013 n=2 ***p< 
0.001). Average ΔΨm values recorded in SH-SY5Y (e) IF1 overexpressing SH-
SY5Y cells (d) and Cyclosporin A treated (f) following elicitation with the Ca2+ 
dependent electrogenic agent Ferrutinin. 
 
Supplementary Fig 3. IF1 controlled activation of targeted autophagy 
during preconditioning 
(a) A representative Western blot of LC3 isoforms I and II and GAPDH in full 
cell lysates of SH-SY5Y and SH-IF1kd cells, control and exposed to IPC 
followed by 24h re-oxygenation (Rx) in presence of 3-Methyladenine (3-MA) 
and Chloroquine (ClQ). (b) The bar graph reports the quantification of LC3-
isoforms I and II expression, normalized on the basis of GAPDH levels and 
expressed as LC3-II/LC3-I ratio (mean value±SEM, SH-SY5Y 
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CTL=0,232±0,026 SH-SY5Y IPC/RX=0,633±0,027 SH-SY5Y 3-MA 
IPC/RX=0,216±0,013 SH-SY5Y ClQ IPC/RX=1,508±0,027 SH-IF1kd 
CTL=0,156±0,022 SH-IF1kd IPC/RX=0,388±0,026 SH-IF1kd 3-MA 
IPC/RX=0,261±0,057 SH-IF1kd ClQ IPC/RX=0,784±0,005 n=2 ***p< 0.001). 
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Supplementary Figure 1. Recombinant IF1 upregulation in primary cortical neurons 
a) IF1 staining in cortical neurons expressing IF1-EYFP and b) The bar graph reports the 
quantification of IF1 fluorescence (mean value±SEM, YFP=100±0 IF1=210,75±11,64 n=3 
*p< 0.05,).  . 
 
Supplementary Figure 2. IF1 profiled expression during re-oxygenation and 
mediated protection to electrogenic depolarization of mitochondria 
a) A representative Western blot of IF1 and F1Fo-ATPsynthase β-subunit in mitochondrial 
fractions of SH-SY5Y cell lysates. SH-SY5Y are divided in following groups: control, 
exposed to IPC without re-oxygenation (-RX) and exposed to IPC followed by 24h of re-
oxygenation (+RX). b) The bar graph reports the quantification of IF1 expression, 
normalized on the basis of F1Fo-ATPsynthase β-subunit levels and expressed as IF1/
ATP-β ratio (mean value±SEM, +Rx CTL=0,616±0,001 +Rx IPC=0,950±0,016 -Rx 
CTL=0,800±0,034 -Rx IPC=0,735±0,042 n=2 ***p<0.001). c) A representative Western 
blot of IF1 and GAPDH in full cell lysates of SH-SY5Y cells. SH-SY5Y are divided in 
following groups: control, exposed to IPC without re-oxygenation (-RX) and exposed to 
IPC followed by 24h of re-oxygenation (+RX). d) The bar graph reports the quantification 
of IF1 expression, normalized on the basis of GAPDH levels and expressed as IF1/
GAPDH ratio (mean value±SEM, +Rx CTL=1,194±0,065 +Rx IPC=2,111±0,098 -Rx 
CTL=0,754±0,009 -Rx IPC=0,937±0,013 n=2 ***p< 0.001). Average ΔΨm values 
recorded in SH-SY5Y (e) IF1 overexpressing SH-SY5Y cells (d) and Cyclosporin A 
treated (f) following elicitation with the Ca2+ dependent electrogenic agent Ferrutinin. 
 
Supplementary Figure 3. IF1 controlled activation of targeted autophagy during 
preconditioning 
a) A representative Western blot of LC3 isoforms I and II and GAPDH in full cell lysates 
of SH-SY5Y and SH-IF1kd cells, control and exposed to IPC followed by 24h re-
oxygenation (Rx) in presence of 3-Methyladenine (3-MA) and Chloroquine (ClQ). b) The 
bar graph reports the quantification of LC3-isoforms I and II expression, normalized on 
the basis of GAPDH levels and expressed as LC3-II/LC3-I ratio (mean value±SEM, SH-
SY5Y CTL=0,232±0,026 SH-SY5Y IPC/RX=0,633±0,027 SH-SY5Y 3-MA IPC/
RX=0,216±0,013 SH-SY5Y ClQ IPC/RX=1,508±0,027 SH-IF1kd CTL=0,156±0,022 SH-
IF1kd IPC/RX=0,388±0,026 SH-IF1kd 3-MA IPC/RX=0,261±0,057 SH-IF1kd ClQ IPC/
RX=0,784±0,005 n=2 ***p< 0.001). 
	  
	  
